GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Valuation Rank

Satellos Bioscience (TSX:MSCL) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Satellos Bioscience Valuation Rank Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Valuation Rank
Comparable Companies
TSX:MBX TSXV:GSD TSX:ATE XCNQ:GLAB TSX:TH TSX:HBP TSXV:TTI XCNQ:ACOG TSXV:DMT TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MSCLF:USA 0IT:Germany
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Website
https://www.satellos.com
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.